First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo
The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex…
News
PT-112 Shows Promise for Heavily Treated Myeloma Patients
Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory…
MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials
The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials…
FDA Approval Sought for Cilta-cel CAR T-cell Therapy
Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults…
FDA Approves Xpovio Triple Combo for Previously Treated Myeloma
The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment…
GSK Seeks Ideas for Improving Life in Myeloma Community
A new initiative by GlaxoSmithKline (GSK) is seeking project proposals that will address key needs for people in the multiple myeloma community. Submissions…
Bispecific Antibody Shows Early, Promising Responses in Trial
PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose…
CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients
Ciltacabtagene autoleucel, an investigational CAR T-cell therapy for multiple myeloma, continues to lead to deep and durable responses in heavily treated patients with relapsed or…
MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) —…
Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients
Cevostamab (BFCR4350A), a bispecific antibody developed by Roche, induces durable and deep responses in heavily pre-treated patients with relapsed or refractory multiple…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL